Rafael Rosell Costa

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer.

Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models.

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.

Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC.

Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.

Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study.

Detección a gran escala de mutaciones de EGFR en NSCLC

Detection and localization of early- and late-stage cancers using platelet RNA.

Ensayo EURTAC

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors.

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer.

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).

Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic Response.

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer.

Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Prima Facie

Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply.

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.